secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0000950170-23-003940
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia Q4 net loss $113.4M, cash $1.3B; NTLA-2002 Phase 2 started, NTLA-2001 pivotal plan on track
--------------------------------------------------------------------------------

- Q4 2022 net loss $113.4M vs $81.2M YoY; R&D expenses rose to $100.0M from $71.2M.
- Cash, equivalents and marketable securities $1.3B as of Dec 31, 2022, up from $1.1B.
- Initiated global Phase 2 study of NTLA-2002 for HAE; submitted IND to FDA for U.S. enrollment.
- Plan to submit IND for NTLA-2001 in ATTR-CM in mid-2023; global pivotal trial expected by year-end 2023.
- IND-enabling activities for NTLA-3001 (AATD lung) with filing planned in 2H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017023003940/0000950170-23-003940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017023003940/ntla-20230223.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-003940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer